US OptionsDetailed Quotes
NKTX241220P2500
- 0.14
- +0.04+40.00%
15min DelayClose Dec 10 16:00 ET
0.15High0.14Low
0.15Open0.10Pre Close6 Volume178 Open Interest2.50Strike Price86.00Turnover84.87%IV5.22%PremiumDec 20, 2024Expiry Date0.01Intrinsic Value100Multiplier9DDays to Expiry0.13Extrinsic Value100Contract SizeAmericanOptions Type-0.4813Delta1.1684Gamma17.79Leverage Ratio-0.0072Theta-0.0003Rho-8.56Eff Leverage0.0016Vega
Nkarta Stock Discussion
Sign in to post a comment
$Nkarta (NKTX.US)$
morning star? bottom now with big vol. buy now?
morning star? bottom now with big vol. buy now?
1
1
$Nkarta (NKTX.US)$
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in my...
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in my...
1
1
$Nkarta (NKTX.US)$ Reuters· 2 mins ago
Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
$Nkarta (NKTX.US)$
boom boom boom boom 💥 getting richer from my room 🤣
$Nkarta (NKTX.US)$
$Nkarta (NKTX.US)$
boom boom boom boom 💥 getting richer from my room 🤣
$Nkarta (NKTX.US)$
$Nkarta (NKTX.US)$
Unsupported feature.
Please use the mobile app.
7
1
$Nkarta (NKTX.US)$
I don't know why I didn't share it in my previous post or why I just thought to share it now 🤷🏽 but here we go. this is what I shared with the group.
I know i said not to buy ibrx because it was too volatile. I've changed my tune because of my biopharma outlook.... want it's twin?
cancer killing cell developer, starting with leukemia! buy rating at 17 (i think it pops to 23, but 19 is the full extension) 👌
see that daily turnaround? that's a bottom
see the accumulation at th...
I don't know why I didn't share it in my previous post or why I just thought to share it now 🤷🏽 but here we go. this is what I shared with the group.
I know i said not to buy ibrx because it was too volatile. I've changed my tune because of my biopharma outlook.... want it's twin?
cancer killing cell developer, starting with leukemia! buy rating at 17 (i think it pops to 23, but 19 is the full extension) 👌
see that daily turnaround? that's a bottom
see the accumulation at th...
Unsupported feature.
Please use the mobile app.
6
3
$Nkarta (NKTX.US)$
I shared this with my group. I like cancer treatment biostocks 😁
$Nkarta (NKTX.US)$
I shared this with my group. I like cancer treatment biostocks 😁
$Nkarta (NKTX.US)$
Unsupported feature.
Please use the mobile app.
2
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
?
$Immuneering (IMRX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$ $S&P 500 Index (.SPX.US)$ $BioAtla (BCAB.US)$ $Gilead Sciences (GILD.US)$ $Affimed NV (AFMD.US)$ $Instil Bio (TIL.US)$ $Nkarta (NKTX.US)$
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
10
1
$Nkarta (NKTX.US)$ Nkarta Has Initiated An Investigator-sponsored Trial Of NKX019, A Cd19-directed Chimeric Antigen Receptor NK-cell Therapy For Systemic Lupus Erythematosus. In June 2024, Nkarta Initiated Ntrust-1 Phase 1 Trial Of NKX019 For Lupus Nephritis
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
8
3
$Nkarta (NKTX.US)$ jesus have some mercy
No comment yet
顺流而上 : I bought 3000 shares today